Signorelli, Flavio; Balbi, Gustavo Guimaraes Moreira; Aikawa, Nadia E; Silva, Clovis Artur Almeida da 
; Kupa, Leonard de Vinci Kanda ; Medeiros-Ribeiro, Ana C; Yuki, Emily F. N; Pasoto, Sandra G; Saad, Carla G. S; Borba Neto, Eduardo Ferreira ; Bonfa, Eloisa Silva Dutra de Oliveira
Subjects: COVID-19, ANTICORPOS ANTIFOSFOLIPÍDEOS, IMUNOGENÉTICA, FATORES DE RISCO, COAGULAÇÃO SANGUÍNEA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SIGNORELLI, Flavio et al. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, v. 31, n. 8, p. 974-984, 2022Tradução . . Disponível em: https://doi.org/10.1177/09612033221102073. Acesso em: 16 nov. 2024.APA
Signorelli, F., Balbi, G. G. M., Aikawa, N. E., Silva, C. A. A. da, Kupa, L. de V. K., Medeiros-Ribeiro, A. C., et al. (2022). Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 31( 8), 974-984. doi:10.1177/09612033221102073NLM
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/09612033221102073Vancouver
Signorelli F, Balbi GGM, Aikawa NE, Silva CAA da, Kupa L de VK, Medeiros-Ribeiro AC, Yuki EFN, Pasoto SG, Saad CGS, Borba Neto EF, Bonfa ESD de O. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome [Internet]. Lupus. 2022 ; 31( 8): 974-984.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1177/09612033221102073
